Randomised controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid

Completed

• Conditions: iver transplantation, rejection, withdrawal of immunosuppressions; Injury, Occupational Diseases, Poisoning; Failure and rejection of transplanted organs and tissues

• Registration Number: ISRCTN16781831
• Lead Sponsor: niversity of Western Ontario (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03-28
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Recipients of liver transplantation at the University of Western Ontario, Canada who had stable graft function (no clinical or biochemical evidence of liver disease) for a minimum of two years were offered TIW if they met the following criteria:
1. No documented rejection episodes for at least 24 months prior to the study
2. A minimum post-transplant follow up period of at least 2 years
3. A history of compliance with medications, blood testing for laboratory analyses and in the case of patients transplanted for alcohol-induced liver disease, abstinence from all alcohol beverages during the study period

Exclusion Criteria

1. Patients requiring triple anti-rejection therapy for frequent or severe episodes of rejection in the past
2. More than one liver transplant
3. Requiring anti rejection therapy for non-liver disorders (psoriasis, rheumatoid arthritis [RA] etc)

Study & Design

• Study Type: Interventional
• Study Design: Not specified